NO20004153L - Farmasøytiske preparater for mÕlrettet erstatning av østrogenmangel i sentralnervesystemet - Google Patents

Farmasøytiske preparater for mÕlrettet erstatning av østrogenmangel i sentralnervesystemet

Info

Publication number
NO20004153L
NO20004153L NO20004153A NO20004153A NO20004153L NO 20004153 L NO20004153 L NO 20004153L NO 20004153 A NO20004153 A NO 20004153A NO 20004153 A NO20004153 A NO 20004153A NO 20004153 L NO20004153 L NO 20004153L
Authority
NO
Norway
Prior art keywords
central nervous
nervous system
transcription
estradiol
oestrogen
Prior art date
Application number
NO20004153A
Other languages
English (en)
Other versions
NO20004153D0 (no
Inventor
Vladimir Patchev
Michael Oettel
Ina Thieme
Sigfrid Schwarz
Wolfgang Roemer
Original Assignee
Jenapharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1998121831 external-priority patent/DE19821831A1/de
Application filed by Jenapharm Gmbh filed Critical Jenapharm Gmbh
Publication of NO20004153D0 publication Critical patent/NO20004153D0/no
Publication of NO20004153L publication Critical patent/NO20004153L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO20004153A 1998-02-20 2000-08-18 Farmasøytiske preparater for mÕlrettet erstatning av østrogenmangel i sentralnervesystemet NO20004153L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19807264 1998-02-20
DE1998121831 DE19821831A1 (de) 1998-05-15 1998-05-15 Pharmazeutische Präparate zur gezielten Substitution des Estrogenmangels im Zentralnervensystem
PCT/DE1999/000353 WO1999042108A1 (de) 1998-02-20 1999-02-10 Pharmazeutische präparate zur gezielten substitution des estrogenmangels im zentralnervensystem

Publications (2)

Publication Number Publication Date
NO20004153D0 NO20004153D0 (no) 2000-08-18
NO20004153L true NO20004153L (no) 2000-10-09

Family

ID=26044035

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004153A NO20004153L (no) 1998-02-20 2000-08-18 Farmasøytiske preparater for mÕlrettet erstatning av østrogenmangel i sentralnervesystemet

Country Status (24)

Country Link
EP (1) EP1056460B1 (no)
JP (1) JP2002503694A (no)
KR (1) KR20010041107A (no)
CN (1) CN1291102A (no)
AT (1) ATE252388T1 (no)
AU (1) AU739071C (no)
BG (1) BG104689A (no)
BR (1) BR9909205A (no)
CA (1) CA2321498A1 (no)
CZ (1) CZ291764B6 (no)
DE (1) DE59907446D1 (no)
EA (1) EA002707B1 (no)
EE (1) EE03906B1 (no)
HU (1) HUP0100742A3 (no)
ID (1) ID27069A (no)
IL (1) IL137727A0 (no)
IS (1) IS5571A (no)
NO (1) NO20004153L (no)
NZ (1) NZ506049A (no)
PL (1) PL342313A1 (no)
SK (1) SK12152000A3 (no)
TR (1) TR200002400T2 (no)
UA (1) UA57830C2 (no)
WO (1) WO1999042108A1 (no)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2253318T3 (es) 2001-11-07 2006-06-01 Schering Ag Cribado in vitro de ligandos del receptor de estrogeno.
CN112189624A (zh) * 2020-09-08 2021-01-08 山东第一医科大学(山东省医学科学院) 一种利用受体基因沉默技术构建和鉴定女性ad模型的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4791099A (en) * 1984-10-29 1988-12-13 Chaovanee Aroonsakul Method of treatment for central nervous system diseases such as Alzheimer's's disease
US4897389A (en) * 1984-10-29 1990-01-30 Chaovanee Aroonsakul Treating central nervous system diseases
DE4239946C2 (de) * 1992-11-27 2001-09-13 Jenapharm Gmbh Estranderivate mit einer 14alpha,15alpha-Methylengruppe und Verfahren zu ihrer Herstellung
US5554601A (en) * 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
DE4338314C1 (de) * 1993-11-10 1995-03-30 Jenapharm Gmbh Pharmazeutische Präparate zur Prophylaxe und Therapie radikalvermittelter Zellschädigungen
DE4429397C2 (de) * 1994-08-09 2003-11-20 Jenapharm Gmbh Estra-1,3,5(10)-trien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
DE19524937A1 (de) * 1995-07-08 1997-01-09 Jenapharm Gmbh Pharmazeutische Präparate zur Prophylaxe und Therapie radikalvermittelter Zellschädigungen und zur medikamentösen Substitution beim Mann
CA2227634A1 (en) * 1995-07-24 1997-02-06 University Of Florida Research Foundation, Inc. Use of non-estrogen polycyclic phenol compounds for the manufacture of a medicament for conferring neuroprotection to cells

Also Published As

Publication number Publication date
SK12152000A3 (sk) 2001-02-12
HUP0100742A2 (hu) 2001-09-28
EE03906B1 (et) 2002-12-16
NO20004153D0 (no) 2000-08-18
IS5571A (is) 2000-07-24
EA200000858A1 (ru) 2001-04-23
BR9909205A (pt) 2000-11-14
CZ291764B6 (cs) 2003-05-14
BG104689A (en) 2001-04-30
UA57830C2 (uk) 2003-07-15
WO1999042108A1 (de) 1999-08-26
EA002707B1 (ru) 2002-08-29
DE59907446D1 (de) 2003-11-27
HUP0100742A3 (en) 2002-07-29
NZ506049A (en) 2002-09-27
EP1056460B1 (de) 2003-10-22
TR200002400T2 (tr) 2000-11-21
AU739071B2 (en) 2001-10-04
ATE252388T1 (de) 2003-11-15
CN1291102A (zh) 2001-04-11
ID27069A (id) 2001-02-22
EP1056460A1 (de) 2000-12-06
CZ20002938A3 (cs) 2001-01-17
JP2002503694A (ja) 2002-02-05
AU2920999A (en) 1999-09-06
PL342313A1 (en) 2001-06-04
CA2321498A1 (en) 1999-08-26
IL137727A0 (en) 2001-10-31
KR20010041107A (ko) 2001-05-15
AU739071C (en) 2002-04-11
EE200000477A (et) 2001-12-17

Similar Documents

Publication Publication Date Title
WO1996019568A3 (en) Stabilized ribozyme analogs
HUP0102483A2 (hu) Androszt-5-én-3béta, 17béta-diolt tartalmazó gyógyszerkészítmények
WO1998027929A3 (de) Therapeutische gestagene zur behandlung von premenstrual dysphoric disorder
TR199800648A1 (xx) �ki veya daha fazla etken madde i�in ila� verme sistemi.
MXPA04001114A (es) Derivados de aminoindazol activos como inhibidores de cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los contienen.
EP1023315A4 (en) METHODS AND PREPARATIONS FOR DESTRUCTING SPECIFIC PROTEINS
ATE214709T1 (de) 14,15-cyclopropanosteroide der 19-norandrostan- reihe, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische präparate
DE59510626D1 (de) Verwendung von kompetitiven progesteronantagonisten für die herstellung von arzneimitteln zur behandlung von dysfunktionellen uterinen blutungen
ES2124905T3 (es) Esteroides antiglucocorticoides destinados al tratamiento de trastornos de ansiedad.
Bi et al. Effects of estrogen, age, and calpain on MAP kinase and NMDA receptors in female rat brain
ATE381533T1 (de) Pharmazeutisch wirksame verbindungen und methoden zu ihrer anwendung
MX9601994A (es) Profarmacos de derivados de paclitaxel.
NZ333232A (en) Use of p-aminophenol derivatives (paracetamol) to treat neurodegenerative disease
NO20004153D0 (no) Farmasøytiske preparater for mÕlrettet erstatning av østrogenmangel i sentralnervesystemet
ES2136581A1 (es) Uso de derivados del acido-2-hidroxi-4-trifluorometilbenzoico para la preparacion de medicamentos utiles para inhibir el factor de transcripcion nuclear nf-kb.
ES2110258T3 (es) Derivados de 1,3,5(10)-estratrieno activos por via oral.
TNSN96016A1 (fr) Utilisation de phenylcyclohexylcarboxamides
WO2001085165A3 (de) Kombination von liponsäure und c1-donoren zur behandlung von störungen des zentralen nervensystems
PT800579E (pt) Veiculos de distribuicao de genes de combinacao
DE59712593D1 (de) Sequentielle estrogen/progesteronantagonist-kombination für die hormonersatz-therapie
Kells et al. AAV-mediated expression of Bcl-xL or XIAP fails to induce neuronal resistance against quinolinic acid-induced striatal lesioning
ATE215556T1 (de) 11beta-arylsubstituierte 14,17-ethano estratriene,verfahren zur herstellung dieser verbindungen, sowie ihre verwendung zur herstellung von arzneimitteln
BR0113618A (pt) 17-metilenoesteróides, processos para a sua preparação e composições farmacêuticas contendo estes compostos
MX9800697A (es) Uso de glicosidos de calendula para el tratamiento de psoriasis.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application